Bayer Looks For New Partner As It Strives To Be A Player In Oncology Market
Nearly a decade after entering the oncology field, Bayer has three products on the market, two candidates in Phase II trials and a dozen more in Phase I trials; at ASCO it will talk to a potential partner about a combination drug study.
You may also be interested in...
Bayer AG is pursuing an acquisition of seed manufacturer Monsanto Co. that would establish agriculture as the largest business unit within the diversified life sciences company, usurping pharmaceuticals as the top revenue generator. Bayer Head of Innovation Kemal Malik said the company’s commitment to pharmaceuticals remains unwavering despite the M&A play.
The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.
Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.